Objective. To determine the direct and indirect costs of SLE in Hong Kong, and to ascertain the relationship between neuropsychiatric SLE (NPSLE) and disease costs. Methods. A retrospective, cross-sectional, non-randomized cost-of-illness study was performed in a tertiary rheumatology specialty centre in Hong Kong. Participants completed questionnaires on sociodemographics, employment status and out-of-pocket expenses. Healthcare resources consumption was recorded by chart review. The occurrence of NPSLE since onset of SLE was determined using the 1999 ACR nomenclature and standard definitions. Mann-Whitney U-test was used to compare disease costs between patients with and without NPSLE. Multiple linear regression was used to determine the predictors of the costs. Results. Three hundred and six Chinese patients were recruited, with a mean age of 41 years and mean disease duration of 9.6 years. A total of 108 NPSLE events were recorded by 83 patients. The most common manifestations were seizure and cardiovascular disease. The mean annual total costs were USD 13 307 per patient. The direct costs dominated the total costs, and the costs of inpatient care contributed 52% of the direct costs. Patients with NPSLE incurred significantly higher direct and indirect costs compared with those without NPSLE. The number of NPSLE events was an independent explanatory variable associated with both direct and indirect costs. Conclusion. The economic impact of SLE in Hong Kong is considerable and patients with NPSLE incur higher disease costs compared with those without NPSLE. Improvement in prevention of end-organ damage, especially neuropsychiatric manifestation, may reduce costs of SLE patients.
Introduction
SLE is a multi-factorial autoimmune disease that primarily affects young women. The patients may suffer frequent disease activity exacerbations and the consequently accumulated organ damage [1] [2] [3] . CNS is one of the most commonly involved organs in SLE. Clinical features of neuropsychiatric SLE (NPSLE) are diverse and heterogeneous, including both central and peripheral nervous systems [4] . NPSLE has been identified as a poor prognostic indicator and it is associated with poor quality of life [5] [6] [7] . High hospitalization rate and high frequency of disability in NPSLE patients has been shown previously [8, 9] . Despite the magnitude of the condition, in contrast to other rheumatic diseases, studies evaluating the economic impact of SLE are scanty [10] [11] [12] [13] . None of the studies investigates the relationship between NPSLE and disease costs and no data are available regarding the economic impact of Chinese patients with SLE. We performed a retrospective, non-randomized cost-of-illness study from 2006 to 2007 in a tertiary rheumatology specialty centre in Hong Kong on Chinese patients with SLE. The study identified the direct, indirect and total costs of patients with SLE in a societal perspective. We also ascertained the relationship between NPSLE and the disease costs.
Methods

Patients and procedures
It was a retrospective non-randomized survey. Three hundred and six consecutive Chinese patients with an SLE diagnosis according to the 1997 ACR revised criteria for the classification of SLE [14] were recruited between January 2006 and August 2007 from the Rheumatology Clinic of the Prince of Wales Hospital in Hong Kong. Patients who were not capable of responding to a questionnaire (e.g. presence of dementia) were excluded. The Ethics Committee of the Chinese University of Hong Kong approved this study, and all patients provided written informed consent.
After informed consent, a questionnaire was administered by a trained interviewer. The questionnaire consisted of information on sociodemographics, employment status, out-of-pocket expenses and non-healthcare facilities utilization. All participants also underwent examination by their treating rheumatologists. Disease activity and damage was assessed using the SLEDAI [15] and the SLICC/ ACR Damage Index (SDI) [16, 17] , respectively. A modified damage index (modified-SDI), which excluded the neuropsychiatric (NP) domain, was used to indicate disease damage other than NP.
After the interview, patients' medical records were reviewed by the attending rheumatologists to retrospectively record the total number of NPSLE events since the onset of SLE. The occurrence of NP manifestation was determined using the 1999 ACR nomenclature and standard definitions for NPSLE [4] .
Costs assessment
Hong Kong's healthcare system is dual partite, with government hospitals and private hospitals [18, 19] . Government hospitals deliver most of the medical services with a market share of 94% [19] . They are heavily subsidized and available to all residents with no private means or medical insurance required. Private hospitals in Hong Kong are relatively small in number, size and custom. Charges of private hospitals vary considerably [18] . In Hong Kong, patients with chronic diseases mainly rely on government hospitals while utilization of private hospital services represents a relatively small percentage [20, 21] . In this study, we recorded both government and private medical services by different methods. Expenses on private hospital facilities were reported by patients as a part of patients' out-of-pocket expenses. Utilization of government hospital services was derived by chart review. We used average per diem cost estimated by the government authority [21] .
Costs were determined from the societal perspective, which meant all costs were relevant. Direct costs represented all the health resources utilization delivered to the patients because of SLE in the previous 12 months, including direct healthcare resources as well as non-healthcare resources. Direct healthcare resources comprised: (i) all visits to healthcare providers, including general practitioners, specialists, physiotherapists, occupational therapists, psychologists and other healthcare providers; (ii) all technical examinations including blood tests, urine tests, imaging tests such as conventional radiographic examinations, CT scan, MRI, ultrasound imaging; (iii) all drugs taken; (iv) emergency room visits; (v) costs of inpatient care (including rehabilitation hospitalization); and (vi) patients' out-of-pocket expenses for health products, non-traditional therapies (such as hydrotherapy, acupuncture and massage), aid devices and private hospital facilities. Direct non-healthcare resources comprised: (i) transportation fee to the healthcare providers; (ii) private household help; and (iii) adaptation to houses.
Indirect costs represented the productivity loss due to SLE. Human capital approach (HCA) was used to calculate productivity loss [22] . For those who were employed, indirect costs were the product of the days of annual sick leave and the mean sex-and job-specific monthly salary of full-time workers in Hong Kong. For those who were unemployed due to SLE, the lost wages based on the mean sex-and job-specific monthly salary of the previous job was calculated as the productivity loss. For those who were housewives or non-SLE-related unemployed, productivity loss was calculated as the product of the number of days off household tasks or daily activity limitation and the sex-specific average annual salary of full-time workers in Hong Kong. Wages were derived from Wage and Payroll Statistics, Census and Statistic Department of Hong Kong.
Statistical analyses
Statistical analyses were performed using The Statistics Package for Social Sciences (SPSS for Windows, version 13.0, 2006, SPSS Inc., Chicago, IL, USA). Results are expressed as mean AE S.D. for normally distributed data. For non-normally distributed data, median and range are expressed as well. Mann-Whitney U-test was used to compare disease costs between patients with and without NPSLE. Kruskal-Wallis test was used to test for differences in clinical features or costs among patients with seizure/ cerebrovascular diseases (CVD)/headache. When a KruskalWallis test revealed significant results, Mann-Whitney U-test by Bonferroni adjustment was used for multiple comparisons (for triple comparisons, P < 0.01 was considered significant).
Univariate correlation and multiple linear regression analyses were used to determine the predictors of direct costs and indirect costs. Because of the skewed nature of costs data, logarithm (base ¼ 10) transformed data were used. The possible predictors included gender, age, disease duration, educational level, SLEDAI scores and the number of NPSLE events since disease onset. Because the number of NPSLE events was included into the regression analyses, we used a modified-SDI score (excluding NP domain of SDI) as a possible predictor.
Results
Sociodemographics, clinical and NPSLE profile
Three hundred and six patients were recruited, with a male to female ratio of 1:25, a mean (S.D.) age of 41 (11) years and a mean (S.D.) disease duration of 9.6 (6.9) years (median 8.7, range 0.1-37). At the time of the assessment, 107 (35%) patients had inactive disease with a SLEDAI of 0. The remaining 199 patients were with a mean (S.D.) SLEDAI of 3.77 (2.69) (median 3, range 1-16). One hundred and ninety-four (63%) patients had a modified-SDI of 0. The remaining 112 patients had a mean (S.D.) modified-SDI of 1.35 (1.04) (median 1, range 1-6).
Eighty-three (26.8%) patients had had a total of 108 NPSLE events. Most patients had had one NPSLE event (64/83, 77%). Fifteen patients had had two NPSLE events and four patients had had more than two. The last NP event occurred within the past 3 years and 1 year in 29/83 (35%) and 14/83 (17%) of these patients, respectively. The most common manifestations were seizures (25 episodes), CVD (24 episodes), headache (19 episodes), mood disorder (11 episodes) and psychosis (seven episodes).
Healthcare resources and costs
During the preceding 1 year, the mean AE S.D. visits to healthcare providers was 7.25 AE 4.27. Visits to rheumatologists were the most frequently seen, followed by ophthalmologists and general practitioners. Ninety-seven percent of the patients were on medications, of which 73% were on prednisone, 55% on antimalarial drugs and 31% on immunosuppressants, including AZA (n ¼ 68, 71%), cyclophosphamide (n ¼ 11, 11%), mycophenolate mofetil (n ¼ 6, 6%), CSA (n ¼ 9, 9%), LEF (n ¼ 8, 8%) and MTX (n ¼ 3, 3%).
The number of technical examinations per patient-year varied from 5 to 159 with a median of 27.5 (mean 35.8 AE 24.5). All the participants reported blood tests (mean 30.4 AE 16.8, median 25, range 5-108) and 44.8% of patients needed urine tests (mean 10.9 AE 10.8, median 6, range 1-51). Eighty-five patients (27.8%) needed image tests, but only 9% of patients had at least one of ultrasound, CT or MRI investigation.
Eighty-three (27%) patients had emergency room visits, with a mean number of 1.6 AE 1.1 (median 1, range 1-6). A total number of 197 inpatient care days were recorded by 82 patients (27%) with a mean duration of 21 AE 40 days (median 7.5, range 1-260). The main cause of hospitalization was clinically active SLE (40%), followed by infection (14%, including HPV infection). Five patients needed rehabilitation hospitalization with a mean duration of 42.8 AE 34.2 days (median 42, range 7-82).
Fifty-three percent of the patients recorded out-of-pocket expenses, mainly on health products (110/306, 36%), nontraditional therapy (58/306, 19%) and private doctor visits (52/306, 17%). Seven percent of the patients used self-paid aid devices, mostly on crutch or wheelchair. Expenses on household help and alteration of houses were reported by only 12 (4%) and 5 (2%) patients, respectively.
More than half of the patients were unemployed. Among those who were still working, 85% needed to take sick leave with a mean duration of 14 AE 32 days (median 6 days). For those who were unemployed, the majority indicated that they were work disabled because of SLE (44%), 85% of which had been unemployed for >12 months. For those who were unemployed but not due to SLE (26%) and homemakers (25%), days off from daily activities or household work due to SLE were reported by 24 and 30% patients, respectively, both with a median duration of 0 days.
We determined the average total costs of the 306 patients with SLE to the society as USD 13 307 per patient-year ( Table 1) . The direct costs dominated the total costs (62%), and the costs of inpatient care contributed 52% of the direct costs. These were followed by the costs of technical examinations (16%), patients' out-of-pocket expenses (14%) and costs of healthcare provider visits (10%). The costs of drugs and emergency room visits represented a relatively small percentage.
Annual costs and NPSLE
There is no significant difference in age, disease duration, employment rate, SLEDAI score and SDI score between patients with and without NPSLE ( Table 2) . Patients with and without NPSLE had a similar number of visits to healthcare providers and emergency rooms. Although patients with NPSLE had a longer inpatient care duration, this did not reach a significant level (P ¼ 0.074). Annual direct costs were nearly twice of patients with NPSLE compared with those without NPSLE (P < 0.001). Most of the direct costs components did not differ between the two groups. However, patients with NPSLE incurred significant higher annual drug costs (P ¼ 0.020), mostly due to the higher percentage of them using neuropsychiatric drugs (35% compared with 10% of those without NPSLE, P < 0.0005). Patients with NPSLE also incurred higher annual indirect costs (P ¼ 0.024). However, there was no significant different in unemployment rate, duration of annual sick leave/unemployment/days off from household task or daily activities limitation between the two groups.
Patients with only seizure (n ¼ 12)/CVD (n ¼ 11)/headache (n ¼ 15) were then selected for comparison. Compared with those with headache, patients with CVD had more disease damage, higher annual direct non-healthcare costs, higher direct costs and total costs. However, the clinical features and costs did not differ between patients with seizure and CVD or between patients with seizure and headache.
Multivariate regression analyses
The results of multiple regression analyses for annual direct and indirect costs are shown in Table 3 . Regression analyses of direct costs showed that disease damage (other than NP damage), disease activity and NPSLE events were independent explanatory variables positively associated with increased direct costs, whereas disease duration was negatively associated with increased direct costs. The independent explanatory variables associated with increased indirect costs was the number of NPSLE events and gender.
Discussion
Our study is the first full economic evaluation on Chinese patients with SLE, and also the first study to determine how NPSLE can influence disease costs. Our results show that SLE has a substantial economic impact on the patients and government in Hong Kong, and the number of NPSLE patients is an independent costs predictor of both direct and indirect costs. Such information will be important in view of the improvement in the survival and prolongation of life of the condition and limited healthcare resources.
The assessment of NPSLE in our study was standard and comprehensive, using the 1999 ACR nomenclature and standard definitions for NPSLE, which includes a broad range from subtle abnormalities of neurocognitive functions to overt manifestations.
Previous studies have shown that NPSLE is associated with a high mortality rate and carries a significant physical and psychological burden in patients with SLE [23] [24] [25] . Our results show that NPSLE also incurs considerable economic burden and the number of NPSLE patients is an independent explanatory variable associated with increased direct and indirect costs. Patients with NPSLE need more technical examinations for accurate diagnosis and more aggressive management strategies, which may explain the high direct costs. Given the potential for NP involvement to affect psychosocial function [26, 27] , which refers to the emotional, behavioural and social aspects of a person's functioning, it is possible that it is an important mechanism for its influence on indirect costs of SLE. We also compared costs between patients with seizure, CVD and headache, which were the most common NPSLE events in our cohort. Our results showed that patients with CVD generated higher direct costs compared with those with headache. However, such comparison may be of limited value due to the relatively small number of patients with seizure/CVD/ headache.
The overall prevalence of NPSLE in our cohort (27%) is lower than that in Caucasians (37-91%) [24, [28] [29] [30] [31] . The most common manifestations in our cohort are seizure disorder and CVD, in contrast to the series in Caucasians in which cognitive dysfunction, headache and mood disorder are among the most common manifestations. Besides genetic, immunological and geographic differences, the retrospective assessment in our study may also lead to an underestimation of the number of NPSLE patients. Secondly, formal neuropsychological testing for subtle cognitive dysfunction is not our routine practice at clinic visits because of cumbersomeness of these tests, which may explain the relatively low prevalence of cognitive dysfunction in our cohort. However, the prevalence and pattern of NPSLE of our cohort is similar to previous studies on Chinese cohorts (19-23%) [32, 33] . Our study shows that patients with NPSLE incur both higher annual direct and indirect costs. Unlike lupus nephritis, much less is known about the ideal treatment of NPSLE and the current therapeutic approach is still empirical and based on clinical experience [34] . Our data provide suggestion that improvements in the management of NPSLE may avoid or delay the high costs associated with NP manifestation, and more attention should be drawn to this area.
We determined the average total cost of patients with SLE to the Hong Kong society as USD 13 307 per patient-year. There are no previous cost-of-illness studies of SLE in Hong Kong. Direct comparison of our results with those of other studies in other countries would be difficult because of different years of evaluation, the cost matrix, and the methods of calculation and the pattern of practice. Consistent with previous studies, inpatient care costs represent the largest proportion of direct costs. The costs of drugs were relatively low in our cohort-only 4% of direct costs. But we may have underestimated the costs of medication since the unit price issued by the government may not reflect the true costs or market prices of the drugs. Besides, differences in the healthcare system may affect the summary costs estimation. Not all the drugs were included into the government hospital's drug formulary and subsidized by the government in Hong Kong. New and high-cost drugs (e.g. mycophenolate mofetil) are not within the reimbursed system and patients have to pay for these drugs by themselves, which may also contribute to the low drug costs in our cohort.
There are limitations to this study. First, the retrospective design may affect the accuracy of the data, particularly that the recall period is long (12 months). Secondly, patients with endstaged renal disease or on dialysis mainly attended by nephrologists are excluded from the cohort. Thirdly, if affordable, some patients may be treated by private sectors through the whole disease course. However, under the well-established public healthcare system of Hong Kong, we believe that this is a minority and should not influence the results. Furthermore, because patients were recruited from the outpatient clinic, most of the participants were with mild disease activity or damage, and we could not assess the costs of patients with active NPSLE. Finally, because of international differences in patients' sociodemographics, treatment practices and healthcare systems, our results may not be generalizable to other populations of SLE.
In conclusion, we performed the first cost-of-illness assessment of Chinese SLE in Hong Kong. The results of our study show that SLE has considerable socioeconomic impact on the society and the individual. Patients with NPSLE incur significantly higher annual direct and indirect costs compared with those without NPSLE. Disease activity, organ damage and the number of NPSLE events are independent explanatory variables associated with increased disease costs. Effective control of disease activity and prevention of end-organ damage, especially NP manifestation, may reduce costs in patients with SLE.
